Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Impact of a stromal 16p11.2 microdeletion on tumor progression, angiogenesis, and pro-oncogenic transcriptional networks
EF 2020-21
Résumé
Cancer represents one of the most lethal and prevalent diseases in North America, largely due to low long-term survival rates associated with late stage, metastatic cancers. As a result, it is imperative that novel therapies are developed that target and block cancer progression. Typically, tumours rely heavily on crosstalk with the surrounding niche to drive initiation, progression and metastasis. As a result, characterization of tumour-niche interactions could reveal key molecular vulnerabilities in cancer, for the development of innovative therapies. 16p11.2 deletion syndrome of Autism Spectrum Disorder (ASD) induces a critical dysregulation of blood vessel formation and maturation in the brains of affected individuals, ultimately resulting in impaired cerebral blood flow. Clinically, individuals with ASD report fewer cases of cancer compared to those without ASD. Preliminary findings show that colorectal cancer growth in 16p11.2 deficient mice is significantly reduced compared to wild-type mice. As a result, I hypothesize that suppression of the 16p11.2 locus will remodel the tumour microenvironment, to create an unsupportive tumour niche that results in reduced tumour growth. Using immunostaining techniques, I intend to characterize tumour niche composition, through staining of various stromal components, such as blood vessels, adipocytes, fibroblasts, etc. Further, I intend to profile the single-cell transcriptome of human colorectal cancer cells grown ex vivo in the presence of 16p11.2 deficient stromal cells. Ultimately, the identification of tumour niche components altered by 16p11.2 deficiency in the surrounding stroma, may uncover novel molecular avenues through which cancer can be targeted to block progression and metastasis.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449775
Name
Haebe Joshua R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Impact of a stromal 16p11.2 microdeletion on tumor progression, angiogenesis, and pro-oncogenic transcriptional networks
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Angiogenesis; Autism Spectrum Disorder; Colorectal Cancer; Stromal Interactions; Tumour Microenvironment
Abstract
Cancer represents one of the most lethal and prevalent diseases in North America, largely due to low long-term survival rates associated with late stage, metastatic cancers. As a result, it is imperative that novel therapies are developed that target and block cancer progression. Typically, tumours rely heavily on crosstalk with the surrounding niche to drive initiation, progression and metastasis. As a result, characterization of tumour-niche interactions could reveal key molecular vulnerabilities in cancer, for the development of innovative therapies. 16p11.2 deletion syndrome of Autism Spectrum Disorder (ASD) induces a critical dysregulation of blood vessel formation and maturation in the brains of affected individuals, ultimately resulting in impaired cerebral blood flow. Clinically, individuals with ASD report fewer cases of cancer compared to those without ASD. Preliminary findings show that colorectal cancer growth in 16p11.2 deficient mice is significantly reduced compared to wild-type mice. As a result, I hypothesize that suppression of the 16p11.2 locus will remodel the tumour microenvironment, to create an unsupportive tumour niche that results in reduced tumour growth. Using immunostaining techniques, I intend to characterize tumour niche composition, through staining of various stromal components, such as blood vessels, adipocytes, fibroblasts, etc. Further, I intend to profile the single-cell transcriptome of human colorectal cancer cells grown ex vivo in the presence of 16p11.2 deficient stromal cells. Ultimately, the identification of tumour niche components altered by 16p11.2 deficiency in the surrounding stroma, may uncover novel molecular avenues through which cancer can be targeted to block progression and metastasis.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Haebe, Joshua R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~